Turn Therapeutics expands GX-03 Phase 2 atopic dermatitis trial to full EASI severity spectrum

• Turn Therapeutics finalized Stage 2 design for its adaptive Phase 2 trial of topical GX-03 in atopic dermatitis following a comprehensive interim analysis.
• Interim results have already been reviewed internally, showing clinically meaningful improvement versus vehicle across a broader range of disease severity than expected.
• The company expanded Stage 2 to enroll about 120-135 patients across the full EASI-defined severity spectrum, aiming to support future regulatory development.
• Stage 2 will test multiple key efficacy outcomes to allow success on more than one measure, rather than relying on a single primary endpoint.
• A webcast scheduled for today will present the interim analysis and the updated Stage 2 plan; enrollment is expected to finish in Q4 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Turn Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-075757), on July 07, 2026, and is solely responsible for the information contained therein.